作者
Al B. Benson,Alan P. Venook,Mohamed A. Adam,George J. Chang,Yi-Jen Chen,Kristen K. Ciombor,Stacey A. Cohen,Harry S. Cooper,Dustin A. Deming,Ignacio Garrido‐Laguna,Jean L. Grem,Paul Haste,J. Randolph Hecht,Sarah E. Hoffe,Steven R. Hunt,Hisham Hussan,Kimberly L. Johung,Nora Joseph,Natalie Kirilcuk,Smitha Krishnamurthi,Midhun Malla,Jennifer K. Maratt,Wells A. Messersmith,Jeffrey A. Meyerhardt,Eric D. Miller,Mary F. Mulcahy,Steven Nurkin,Michael J. Overman,Aparna Parikh,Hitendra Patel,Katrina Pedersen,Leonard B. Saltz,Charles Schneider,David Shibata,Benjamin D. Shogan,John M. Skibber,Constantinos T. Sofocleous,Anna Tavakkoli,Christopher G. Willett,Christina Wu,Lisa A. Gurski,Jenna Snedeker,Frankie Jones
摘要
Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. Management of disseminated metastatic CRC involves various active drugs, either in combination or as single agents. The choice of therapy is based on consideration of the goals of therapy, the type and timing of prior therapy, the mutational profile of the tumor, and the differing toxicity profiles of the constituent drugs. This manuscript summarizes the data supporting the systemic therapy options recommended for metastatic CRC in the NCCN Guidelines for Colon Cancer.